This is a nonrandomized (participants may decide which drugs they want to take), multi-site, open-label trial to evaluate a novel two-drug combination regimen (MK-3682 450 mg + ruzasvir [RZR; MK-8408] 180 mg once daily [q.d.] for 12 weeks) in male and female treatment-naïve (TN taken once-a-day) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.
Efficacy and Safety of MK-3682 + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
To read the entire clinical trial description, click here
The study is evaluating the combination of sofosbuvir plus velpatasvir (Epclusa). The combination was recently approved in the United States to treat all genotypes. The cure rates are up to and over 90%.
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic Hepatitis C Virus Infection
To read the entire clinical trial description, click here…
The study is evaluating the dose of sofosbuvir plus ribavirin in adolescent patients—aged 12 to 17 yo—infected with HCV genotype 2 and 3. Once the dose is determined the same adolescent patients will be treated with the combination of sofosbuvir plus ribavirin.
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
To view the entire clinical trial description, click here
This is an observation study to find out the ‘real world’ effectiveness (cure) of AbbVie’s Viekira Pak (with and without ribavirin) in genotype 1 and 4 patients. This includes treatment-naïve and treatment experienced patients. AbbVie’s drug combinations are approved by the Food and Drug Administration (FDA) to treat hepatitis C genotype 1 (cure rates = 95 to 100%).
Russia: Real World Evidence of the Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation – An Observational, Multi-Center Study (HCV RWE)
To read the entire study description, click here
The study is recruiting HIV/HCV coinfected people with genotype 1 through 6 to determine the safety and effectiveness of the combination of ABT-493 plus ABT-530. The study is enrolling non-cirrhotic patients who will be treated for 8 weeks and compensated cirrhotic patients who will be treated for 12 weeks. In the completed Phase II studies the combination cured 97% to 100% of HCV genotype 1, 2 and 3 patients.
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)
To view the entire study description click here